Production (Stage)
Camp4 Therapeutics Corporation
CAMP
$2.00
-$0.005-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 858.00K | 652.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 858.00K | 652.00K | -- | -- | -- |
| Cost of Revenue | 10.15M | 10.00M | 9.70M | 9.56M | 9.74M |
| Gross Profit | -9.29M | -9.34M | -9.70M | -9.56M | -9.74M |
| SG&A Expenses | 3.81M | 4.69M | 3.81M | 3.20M | 3.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.96M | 14.69M | 13.52M | 12.77M | 12.88M |
| Operating Income | -13.10M | -14.03M | -13.52M | -12.77M | -12.88M |
| Income Before Tax | -12.43M | -13.28M | -13.48M | -12.51M | -12.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.43M | -13.28M | -13.48M | -12.51M | -12.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.43M | -13.28M | -13.48M | -12.51M | -12.45M |
| EBIT | -13.10M | -14.03M | -13.52M | -12.77M | -12.88M |
| EBITDA | -12.68M | -13.62M | -13.10M | -12.34M | -12.44M |
| EPS Basic | -0.62 | -0.77 | -24.19 | -26.28 | -26.57 |
| Normalized Basic EPS | -0.39 | -0.48 | -15.12 | -16.43 | -16.60 |
| EPS Diluted | -0.62 | -0.77 | -24.19 | -26.28 | -26.57 |
| Normalized Diluted EPS | -0.39 | -0.48 | -15.12 | -16.43 | -16.60 |
| Average Basic Shares Outstanding | 20.15M | 17.25M | 557.40K | 476.20K | 468.70K |
| Average Diluted Shares Outstanding | 20.15M | 17.25M | 557.40K | 476.20K | 468.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |